was diagnose with covid19 from a previous exposure to getting the booster dose; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (was diagnose with covid19 from a previous exposure to getting the booster dose) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 006D21A, 007M20A and 038K20A) for COVID-19 vaccination.     No Medical History information was reported.   On 28-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 25-Feb-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 25-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 28-Oct-2021, the patient experienced COVID-19 (was diagnose with covid19 from a previous exposure to getting the booster dose). At the time of the report, COVID-19 (was diagnose with covid19 from a previous exposure to getting the booster dose) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 27-Oct-2021, SARS-CoV-2 test: negative (Negative) Negative. On 28-Oct-2021, SARS-CoV-2 test: positive (Positive) Positive.     For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   No concomitant medications were provided.  No treatment medications were provided.  This spontaneous case of drug ineffective concerns a 66-year-old female patient with no relevant medical history reported, who experienced non-serious unexpected event of special interest (AESI) COVID-19. The event occurred 3 days after the third dose of the Moderna COVID-19 Vaccine (mRNA-1273), respectively. Reportedly, one day after the booster dose, the patient experienced rhinorrhoea, chills, headache and myalgia and did the first rapid test that was negative for COVID-19. The patient had similar symptoms with prior doses. However, three days after vaccination, the patient was tested again and the result was positive for COVID-19. Rechallenge was not applicable since the events occurred after the third dose so, no rechallenge was done and recurrence was not applicable.  The benefit-risk relationship of drug is not affected by this report.   Most recent FOLLOW-UP information incorporated above includes: On 01-Nov-2021: Follow-up received contains significant information: Reporter's and patient information updated, additional events updated.; Sender's Comments: This spontaneous case of drug ineffective concerns a 66-year-old female patient with no relevant medical history reported, who experienced non-serious unexpected event of special interest (AESI) COVID-19. The event occurred 3 days after the third dose of the Moderna COVID-19 Vaccine (mRNA-1273), respectively. Reportedly, one day after the booster dose, the patient experienced rhinorrhoea, chills, headache and myalgia and did the first rapid test that was negative for COVID-19. The patient had similar symptoms with prior doses. However, three days after vaccination, the patient was tested again and the result was positive for COVID-19. Rechallenge was not applicable since the events occurred after the third dose so, no rechallenge was done and recurrence was not applicable.  The benefit-risk relationship of drug is not affected by this report.